Skip to content
Menu

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.

Read at benzinga.com

← All stock news